Alan B Cash5033 Seachase St, San Diego, CA 92130

6881010, Apr 19, 2005

Mar 17, 2003

10/391468

Alan Brian Cash - San Diego CA, US

B09B001/00

40512957, 40512965, 4051297, 210747

A system for the onsite storage, treatment and disposal of contaminated soils and sediments includes a trench that is excavated at the site. The trench is formed with a bottom surface that includes a sump reservoir and a sloped portion oriented to feed liquids into the sump reservoir. An impervious liner is positioned in the trench to prevent leakage into the surroundings. A sump system that includes the sump reservoir, drain tubes and geotextile netting is disposed in the trench to transfer fluids between the sump reservoir and the contaminated material. A geotextile filter sheet is positioned over the sump system allowing fluid transfer between the sump system and the contaminated material while preventing solids from entering the sump system. An access pipe allows fluids to be introduced into and withdrawn from the sump reservoir to accomplish various treatment methods including de-watering, vapor extraction, bioremediation, surfactant washing and solvent extraction.

2004008, May 6, 2004

Nov 4, 2002

10/288049

Alan Cash - San Diego CA, US

A62D003/00

588/207000

A method for reducing the toxicity of incineration ash containing dioxin-type compounds includes the step of contacting the contaminated incineration ash with an aqueous solution of an alkaline earth metal hydroxide. Detoxification occurs at relatively low temperatures (e.g. below 350 degrees Celsius) and can be performed in the presence of water that is often found in incineration ash storage piles. The solution and ash are kept in contact for a pre-determined detoxification period. Once detoxification has progressed to a desired endpoint, the solution is drained to a storage vessel where it can be re-used to treat additional incineration ash. In one implementation, the treatment is performed at a slightly elevated temperature (e.g. 100 degrees Celsius) to reduce the length of the detoxification period while maintaining the same level of detoxification.

2008027, Nov 13, 2008

Dec 15, 2005

11/792703

Alan B. Cash - San Diego CA, US

A61K 9/12
C07C 69/34
A61K 31/225
A61K 8/37
C12N 5/06
A61P 35/02
A61K 38/43
A61K 38/02

424 45, 560190, 514547, 424 941, 514 2, 424 59, 435375

A method and composition for extending the lifespan of an individual and delaying the onset of age-related disease is provided. The method includes the administration of an effective dose of oxaloacetate, wherein the oxaloacetate acts to mimic the cellular conditions obtained under caloric restriction to provide similar benefits. The invention further includes methods and compositions for reducing the incidence or treatment of cancer. Compositions and methods for reducing body fat by administering an effective amount of oxaloacetate are likewise provided. Compositions for DNA repair in UV damaged cells is provided are also provided. Similarly, a method for treating a hang-over comprising administering an effective amount of oxaloacetate is disclosed.

2011006, Mar 17, 2011

Mar 11, 2009

12/922036

Alan Brian Cash - San Diego CA, US

A23L 1/22
A23G 4/06
A23L 2/56
A23L 1/24
A23G 3/36
A23L 1/237
A61K 8/37

424 49, 426536, 426 3, 426321, 4263303, 426330, 426654, 426590, 426589

Provided herein is a method for flavoring an ingestible composition with an organoleptically effective amount of the flavoring agent. The flavoring agent may be used in a wide variety of ingestible vehicles such as chewing gum compositions, hard and soft confections, toothpaste, dairy products, beverage products including juice drinks and juice products, green vegetable and chicken products, salad dressings, deserts, bottled water, frozen treats and the like. The present invention also pertains to an ingestible composition comprising an ingestible vehicle and an organoleptically effective amount of the purified flavoring agent. The present invention also pertains to oxaloacetic acid and salts of oxaloacetic acid, represented by the formula, HOOCCH2CO—COOH and salts of the same. The invention further uses oxaloacetic acid and salts of oxaloacetic acid as a method to preservative in the preparation of ingestible compositions, without increase in toxicity. The invention further uses oxaloacetic acid as a ingestible acidizer, without increase in toxicity.

2013014, Jun 6, 2013

Jun 22, 2011

13/806465

Alan B. Cash - San Diego CA, US

A61K 31/198
A61K 31/194
A61K 31/375
A61K 45/06
A61K 31/4439
A61K 31/427
A61K 31/155
A61K 31/19

514342, 514574, 562582, 514474, 514369, 206461

The present invention relates to oxaloacetate compounds that activate AMP-activated protein kinase (AMPK), including the preparation of the compounds, compositions containing the compounds, preserving said compounds and the use of the compounds in the prevention or treatment of disorders such as diabetes, metabolic syndrome, obesity, cardiovascular disease, Alzheimer's disease, and cancer.

6027651, Feb 22, 2000

Oct 26, 1998

9/178056

Alan B. Cash - San Diego CA

C02F 104
C02F 128

210662

A process for regenerating a solvent from a waste extract after use in a remediation process includes monitoring the water content and the amount of organic contaminants in the extract. If the water content in the extract is above a predetermined threshold value, the extract is distilled to yield the solvent therefrom for reuse in the remediation process. If the water content is below the threshold value but the amount of organic contaminants is above a predetermined limit, the extract is also distilled to yield the solvent therefrom for reuse. If the water content and amount of organic contaminants are both below their respective predetermined parameters, the extract is filtered through a molecular sieve to yield the solvent therefrom. The yield solvent is then collected from the distillation and filtering processes, and the regenerated solvent is then reused in the remediation process.

2021030, Oct 7, 2021

Jun 22, 2021

17/354866

- San Diego CA, US
Alan B. CASH - San Diego CA, US

A61K 31/194
A61K 31/167
A61K 31/192
A61K 31/4402
A61K 31/522

The invention relates to methods for treating symptoms of PMS and PMDD including muscle ache, bloating, cramping, acne, tender breasts, bloating, fatigue, difficulty concentrating, diminished impulse control, irritability, anxiety, tension, anger, depression, insomnia and/or rapid fluctuations in mood (mood swings). The method comprises administration of a pharmaceutical composition comprising oxaloacetate, oxaloacetate salts, oxaloacetic acid and/or anhydrous enol-oxaloacetate.

2019032, Oct 24, 2019

Sep 21, 2017

16/335652

Alan B. CASH - San Diego CA, US

A61K 31/194
A61K 31/192
A61K 31/167
A61K 31/4402
A61K 31/522

The invention relates to methods for treating symptoms of PMS and PMDD including muscle ache, bloating, cramping, acne, tender breasts, bloating, fatigue, difficulty concentrating, diminished impulse control, irritability, anxiety, tension, anger, depression, insomnia and/or rapid fluctuations in mood (mood swings). The method comprises administration of a pharmaceutical composition comprising oxaloacetate, oxaloacetate salts, oxaloacetic acid and/or anhydrous enol-oxaloacetate.